MD3440105T2 - Receptori de celulă T - Google Patents

Receptori de celulă T

Info

Publication number
MD3440105T2
MD3440105T2 MDE20190184T MDE20190184T MD3440105T2 MD 3440105 T2 MD3440105 T2 MD 3440105T2 MD E20190184 T MDE20190184 T MD E20190184T MD E20190184 T MDE20190184 T MD E20190184T MD 3440105 T2 MD3440105 T2 MD 3440105T2
Authority
MD
Moldova
Prior art keywords
tcrs
cell receptors
mage
tcr
hla
Prior art date
Application number
MDE20190184T
Other languages
English (en)
Inventor
Conor Hayes
Linda Hibbert
Nathaniel Liddy
Tara Mahon
Marine Raman
Original Assignee
Immunocore Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunocore Ltd filed Critical Immunocore Ltd
Publication of MD3440105T2 publication Critical patent/MD3440105T2/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Abstract

Prezenta invenţie se referă la receptorii de celule T (TCR) care leagă peptida restricţionată HLA-A*02 GVYDGREHTV (SECV ID NR: 1) derivată din antigenul cancerului germinal MAGE A4. TCR-urile menţionate pot cuprinde mutaţii nenaturale în domeniile variabile alfa şi/sau beta în raport cu un TCR MAGE A4 nativ. TCR-urile invenţiei sunt potrivite în particular pentru a fi utilizate ca noi reactivi imunoterapeutici pentru tratamentul bolilor maligne.
MDE20190184T 2016-04-08 2017-04-07 Receptori de celulă T MD3440105T2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201606009 2016-04-08
PCT/GB2017/050985 WO2017175006A1 (en) 2016-04-08 2017-04-07 T cell receptors

Publications (1)

Publication Number Publication Date
MD3440105T2 true MD3440105T2 (ro) 2022-09-30

Family

ID=58548761

Family Applications (1)

Application Number Title Priority Date Filing Date
MDE20190184T MD3440105T2 (ro) 2016-04-08 2017-04-07 Receptori de celulă T

Country Status (29)

Country Link
US (2) US11505590B2 (ro)
EP (2) EP4023668A1 (ro)
JP (1) JP7254519B2 (ro)
KR (1) KR102473964B1 (ro)
CN (1) CN109563148B (ro)
AU (2) AU2017246693B2 (ro)
BR (1) BR112018070741A2 (ro)
CA (1) CA3020214A1 (ro)
CL (1) CL2018002859A1 (ro)
CO (1) CO2018011972A2 (ro)
CR (1) CR20180531A (ro)
DK (1) DK3440105T3 (ro)
ES (1) ES2914648T3 (ro)
HR (1) HRP20220865T1 (ro)
HU (1) HUE059159T2 (ro)
IL (2) IL262144B2 (ro)
LT (1) LT3440105T (ro)
MA (1) MA44608B1 (ro)
MD (1) MD3440105T2 (ro)
MX (1) MX2018012318A (ro)
MY (1) MY198621A (ro)
PE (1) PE20190335A1 (ro)
PH (1) PH12018502158A1 (ro)
PL (1) PL3440105T3 (ro)
PT (1) PT3440105T (ro)
RS (1) RS63371B1 (ro)
SG (1) SG11201808797XA (ro)
SI (1) SI3440105T1 (ro)
WO (1) WO2017175006A1 (ro)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3020530A1 (en) * 2016-04-08 2017-10-12 Adaptimmune Limited T cell receptors
MX2018012268A (es) 2016-04-08 2019-02-07 Adaptimmune Ltd Receptores de celulas t.
EP4215543A3 (en) 2017-10-03 2023-10-11 Juno Therapeutics, Inc. Hpv-specific binding molecules
WO2019133443A1 (en) * 2017-12-28 2019-07-04 Janux Therapeutics, Inc. Modified t cell receptors
GB201803750D0 (en) 2018-03-08 2018-04-25 Immunocore Ltd Method
BR112020020245A2 (pt) * 2018-04-05 2021-04-06 Editas Medicine, Inc. Métodos de produzir células expressando um receptor recombinante e composições relacionadas
CA3126611A1 (en) 2019-01-17 2020-07-23 Immunocore Limited Formulations of soluble t cell receptor(tcr) and single chain fragment variable (scfv) bispecific proteins
GB201901306D0 (en) 2019-01-30 2019-03-20 Immunocore Ltd Multi-domain binding molecules
GB201901305D0 (en) 2019-01-30 2019-03-20 Immunocore Ltd Specific binding molecules
EP3714941A1 (en) * 2019-03-27 2020-09-30 Medigene Immunotherapies GmbH Mage-a4 tcrs
CN114585646A (zh) * 2019-06-18 2022-06-03 里珍纳龙药品有限公司 Mage-a4 t细胞受体及其使用方法
CA3142513A1 (en) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
JP7296467B2 (ja) 2019-12-18 2023-06-22 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｈｌａ－ａ２／ｍａｇｅ－ａ４に結合する抗体
BR112022014623A2 (pt) 2020-02-14 2022-09-13 Jounce Therapeutics Inc Anticorpos e proteínas de fusão que se ligam a ccr8 e usos dos mesmos
EP4153633A1 (en) * 2020-05-19 2023-03-29 Amgen Inc. Mageb2 binding constructs
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
CA3210289A1 (en) 2021-03-09 2022-09-15 Anna Maria SOBIERAJ Mage-a4 peptide-mhc antigen binding proteins
TW202313094A (zh) 2021-05-18 2023-04-01 美商基利科學股份有限公司 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
WO2023076983A1 (en) 2021-10-28 2023-05-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
AU2022376954A1 (en) 2021-10-29 2024-05-02 Gilead Sciences, Inc. Cd73 compounds
TW202328212A (zh) 2021-12-01 2023-07-16 英商英美偌科有限公司 Ｍａｇｅ—ａ４陽性癌症之治療
US20230242508A1 (en) 2021-12-22 2023-08-03 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023122581A2 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
TW202346277A (zh) 2022-03-17 2023-12-01 美商基利科學股份有限公司 Ｉｋａｒｏｓ鋅指家族降解劑及其用途
TW202400138A (zh) 2022-04-21 2024-01-01 美商基利科學股份有限公司 Ｋｒａｓ ｇ１２ｄ調節化合物
CN117106060A (zh) * 2022-05-17 2023-11-24 香雪生命科学技术（广东）有限公司 一种识别mage的高亲和力t细胞受体及其应用
US20240116928A1 (en) 2022-07-01 2024-04-11 Gilead Sciences, Inc. Cd73 compounds
US20240092859A1 (en) 2022-08-18 2024-03-21 Immunocore Ltd T cell receptors and fusion proteins thereof
WO2024038183A1 (en) 2022-08-18 2024-02-22 Immunocore Limited Multi-domain binding molecules
WO2024038193A1 (en) 2022-08-18 2024-02-22 Immunocore Limited Multi-domain binding molecules
WO2024038198A1 (en) 2022-08-18 2024-02-22 Immunocore Limited Multi-domain binding molecules
US20240091262A1 (en) 2022-09-14 2024-03-21 Cdr-Life Ag Mage-a4 peptide dual t cell engagers

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0977886A4 (en) 1997-03-07 2002-10-23 Sunol Molecular Corp FUSION PROTEINS, WHICH CONTAIN A BACTERIOPHAGE ENVELOPE PROTEIN AND A SINGLE CHAIN T-CELL RECEPTOR
KR100712256B1 (ko) 1997-10-02 2007-04-27 알토 바이오사이언스 코포레이션 가용성 단일쇄 ｔ-세포 수용체 단백질
WO2000020445A2 (en) 1998-10-02 2000-04-13 Ludwig Institute For Cancer Research Tumor antigens and ctl clones isolated by a novel procedure
DE60040556D1 (de) 1999-12-06 2008-11-27 Univ Illinois Hochaffine t-zellrezeptorproteine und verfahren
WO2001062908A2 (en) 2000-02-22 2001-08-30 Ahuva Nissim Chimeric and tcr phage display libraries, chimeric and tcr reagents and methods of use thereof
PT1421115E (pt) 2001-08-31 2005-07-29 Avidex Ltd Receptor de celulas t soluvel
AU2003289716A1 (en) 2002-09-12 2004-04-30 Incyte Corporation Molecules for diagnostics and therapeutics
US7569664B2 (en) 2002-10-09 2009-08-04 Immunocore Limited Single chain recombinant T cell receptors
ATE432290T1 (de) 2002-11-09 2009-06-15 Immunocore Ltd T ZELL REZEPTOR ßDISPLAYß
GB0304068D0 (en) * 2003-02-22 2003-03-26 Avidex Ltd Substances
AU2006228308B2 (en) 2005-04-01 2012-05-17 Adaptimmune Limited High affinity HIV T cell receptors
US8003770B2 (en) 2005-09-13 2011-08-23 Mie University T-cell receptor and nucleic acid encoding the receptor
GB0908613D0 (en) 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
CA2848209C (en) 2011-09-15 2021-06-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing hla-a1- or hla-cw7-restricted mage
JP2015502915A (ja) * 2011-10-14 2015-01-29 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド ＣＤ１ｄに対する抗体
DK2771357T3 (en) 2011-10-28 2018-10-29 Regeneron Pharma Genetically modified T cell receptor mice
GB201223172D0 (en) 2012-12-21 2013-02-06 Immunocore Ltd Method
EP3747899A3 (en) * 2013-01-29 2021-02-24 Max-Delbrück-Centrum für Molekulare Medizin (MDC) High avidity binding molecules recognizing mage-a1
ES2746240T3 (es) 2013-03-13 2020-03-05 Health Research Inc Composiciones y procedimientos para la utilización de receptores de células T recombinantes para el reconocimiento directo de un antígeno tumoral
US10927160B2 (en) * 2014-07-09 2021-02-23 The Regents Of The University Of California Engineered invariant natural killer T (iNKT) cells and methods of making and using thereof
WO2016022400A1 (en) 2014-08-04 2016-02-11 Fred Hutchinson Cancer Research Center T cell immunotherapy specific for wt-1
WO2016166630A1 (en) 2015-04-13 2016-10-20 Pfizer Inc. Chimeric antigen receptors targeting b-cell maturation antigen
TWI826891B (zh) 2016-03-16 2023-12-21 德商英麥提克生物技術股份有限公司 轉染 t 細胞和 t 細胞受體用於癌症免疫治療
TW202313671A (zh) 2016-04-01 2023-04-01 美商凱特製藥公司 嵌合抗原和ｔ細胞受體及使用方法

Also Published As

Publication number Publication date
SI3440105T1 (sl) 2022-07-29
AU2022256131A1 (en) 2022-11-24
IL262144A (en) 2018-11-29
BR112018070741A2 (pt) 2019-02-12
WO2017175006A1 (en) 2017-10-12
HRP20220865T1 (hr) 2022-10-14
IL262144B1 (en) 2023-12-01
JP2019516357A (ja) 2019-06-20
JP7254519B2 (ja) 2023-04-10
ES2914648T3 (es) 2022-06-15
EP3440105A1 (en) 2019-02-13
CO2018011972A2 (es) 2019-02-08
RU2018135248A (ru) 2020-05-12
AU2017246693A1 (en) 2018-11-22
CA3020214A1 (en) 2017-10-12
US20230322895A1 (en) 2023-10-12
US11505590B2 (en) 2022-11-22
MY198621A (en) 2023-09-11
MX2018012318A (es) 2019-07-04
RS63371B1 (sr) 2022-08-31
RU2018135248A3 (ro) 2020-09-23
MA44608B1 (fr) 2022-06-30
CN109563148A (zh) 2019-04-02
MA44608A (fr) 2019-02-13
AU2017246693B2 (en) 2022-07-21
CL2018002859A1 (es) 2019-04-26
IL262144B2 (en) 2024-04-01
HUE059159T2 (hu) 2022-10-28
PE20190335A1 (es) 2019-03-07
KR102473964B1 (ko) 2022-12-06
PT3440105T (pt) 2022-05-31
US20190092834A1 (en) 2019-03-28
KR20180132844A (ko) 2018-12-12
CR20180531A (es) 2019-06-13
PH12018502158A1 (en) 2019-07-15
DK3440105T3 (da) 2022-06-13
PL3440105T3 (pl) 2022-08-29
EP3440105B1 (en) 2022-04-27
LT3440105T (lt) 2022-05-25
CN109563148B (zh) 2022-10-14
SG11201808797XA (en) 2018-11-29
EP4023668A1 (en) 2022-07-06
IL308831A (en) 2024-01-01

Similar Documents

Publication Publication Date Title
MD3440105T2 (ro) Receptori de celulă T
ZA202306640B (en) T cell receptors
MY196179A (en) T Cell Receptors Specific for the NY-ESO-1 Tumor Antigen-Hla-A*02 Complex
PH12020500078A1 (en) Anti-ctla-4 antibodies and uses thereof
PH12018501882A1 (en) Binding proteins and methods of use thereof
PH12018500664A1 (en) Anti-lag3 antibodies and uses thereof
MX2017010793A (es) Terapeuticos de anticuerpo que ligan cd137.
NZ756678A (en) Anti-lag-3 antibodies and uses thereof
MY186974A (en) Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof
MD3601358T2 (ro) Anticorpi anti-TREM2 și metode de utilizare a acestora
EA201791706A1 (ru) Связывающие icos белки
MD4716C1 (ro) Anticorpi anti-LAG3 şi fragmente de legare a antigenului
EA201690180A1 (ru) Т-клеточные рецепторы
MX2017001599A (es) Anticuerpos novedosos y sus usos.
TN2019000294A1 (en) Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
MY166776A (en) Humanised anti-ctla4 antibodies
PH12020550933A1 (en) Antibodies binding ctla-4 and uses thereof
EA201591072A1 (ru) Антитела против pdgfr-бета и их применения
EA201691836A1 (ru) Антитела к mcam и соответствующие способы их применения
MA34004B1 (fr) Protéines de liaison à cd127
EA202190138A1 (ru) Анти-sirp-бета1 антитела и способы их использования
SI3030259T1 (en) Peptides
MX2022004194A (es) Anticuerpos contra el receptor de virus de la polio (pvr) y usos de los mismos.
MX2019000887A (es) Proteínas de fusión de fragmentos de proteínas humanas para crear composiciones de fc de inmunoglobina multimerizadas en un orden con unión mejorada al receptor de fc.
MX2022009704A (es) Receptores de antigenos quimericos con mutaciones de cd28 y uso de los mismos.